secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scopus BioPharma Inc. (—)
CIK:        0001772028
Form:       8-K
Filed at:   2022-12-02T23:59:59+00:00
Accession:  0001104659-22-124179
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Scopus BioPharma receives Nasdaq public reprimand for listing non-compliance; final extension to Jan 9, 2023
--------------------------------------------------------------------------------

- Nasdaq publicly reprimanded Scopus for failing to comply with Listing Rule 5250(a)(1) regarding timely notification.
- Company missed milestone dates in its Compliance Plan and did not inform Nasdaq; granted final extension to Jan 9, 2023.
- Must satisfy Minimum Bid Price ($1.00), MVLS ($50M), and MVPHS ($15M) requirements by Jan 9 or face delisting.
- Failure to comply would likely have a material adverse effect on trading and value of the common stock.
- Company continues best efforts but cannot assure compliance; delisting risk remains significant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1772028/000110465922124179/0001104659-22-124179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1772028/000110465922124179/tm2231893d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-124179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer